Current recommendations for the treatment of genital herpes

Drugs

Volumn 60, Issue 6, 2000, Pages 1329-1352

  Leung, Daniel T ^a   Sacks, Stephen L ^b  

^a WAKE FOREST UNIVERSITY   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON; CIDOFOVIR; CROFELEMER; DISABLED INFECTIOUS SINGLE CYCLE VACCINE; DNA VACCINE; EDOXUDINE; FAMCICLOVIR; FOSCARNET; GLYCOPROTEIN B; GLYCOPROTEIN D; HERPES VACCINE; IMMUNOLOGICAL ADJUVANT; LOBUCAVIR; NUCLEOSIDE ANALOG; PENCICLOVIR; RESIQUIMOD; TRIFLURIDINE; UNCLASSIFIED DRUG; VALACICLOVIR;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DISEASE TRANSMISSION; DRUG EFFICACY; EPIDEMIC; GENITAL HERPES; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE DEFICIENCY; PALLIATIVE THERAPY; PREGNANCY; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVIEW; VACCINATION; VIRUS RESISTANCE; VIRUS SHEDDING;

2-AMINOPURINE; ACYCLOVIR; ANTIVIRAL AGENTS; DRUG RESISTANCE, MICROBIAL; FEMALE; HERPES GENITALIS; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 2, HUMAN; HUMANS; INTERFERON TYPE I; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RECURRENCE; VACCINES, DNA; VIRUS SHEDDING;

EID: 0034525315     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060060-00007     Document Type: Review

References (228)

1. Genital herpes simplex virus infection and treatment
2. Recurrence rates in genital herpes after symptomatic first-episode infection
3. Herpes simplex virus-2 infection: An emerging disease?
4. Herpes simplex virus type 2 in the United States, 1976 to 1994
5. A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States
6. Risk factors for the sexual transmission of genital herpes
7. 9-(2-hydroxyethoxymethyl)guanine activity against viruses of the herpes group
8. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine
9. Inhibition of purified human and herpes simplex virus-induced DNA polymerases by 9-(2-hydroxyethoxymethyl)guanine triphosphate: Effects on primer-template function
10. Acyclovir triphosphate is a suicide inactivator of the herpes simplex virus DNA polymerase
11. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine
12. Pharmacokinetics of acyclovir after intravenous and oral administration
13. Metabolic disposition of the acyclovir prodrug valaciclovir in the rat
14. Purification and characterization of an enzyme from rat liver that hydrolyzes 25 GU 87, the L-valyl ester prodrug of acyclovir
15. Metabolism and pharmacokinetics of the acyclovir prodrug BW 256U 87 in cynomolgus monkeys
16. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans
17. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single-dose and multiple-dose administration to normal volunteers
18. Phase I pharmacokinetics of the acyclovir prodrug, valaciclovir
19. Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy
20. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis
21. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults
22. Valaciclovir for the suppression of recurrent genital HSV infection: A placebo-controlled study of once-daily therapy
23. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection
24. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation
25. The mode of action of penciclovir
26. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) in cell culture
27. Famciclovir and penciclovir: The mode of action of famciclovir including its conversion to penciclovir
28. Pharmacokinetics of famciclovir in man
29. Mode of antiviral action of penciclovir in MRC-5 cells infected cells with herpes simplex virus type-I (HSV-I), HSV-2, and varicella-zoster virus
30. Selection of an oral prodrug (BRL42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine; penciclovir]
31. In vitro activities of penciclovir and acyclovir against herpes simplex virus types 1 and 2
32. Resistance of herpesvirus to antiviral drugs
33. Comparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunosuppression model
34. The effects of delayed-onset chemotherapy using famciclovir or valaciclovir in a murine immunosuppression model for HSV-1
35. Differential effects of famciclovir and valaciclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency
36. Safety of famciclovir in patients with herpes zoster and genital herpes
37. Drug interaction studies and safety of famciclovir in healthy volunteers: A review
38. Pharmacokinetics of penciclovir in healthy elderly subjects following a single oral administration of 750mg famciclovir
39. Effect of food on bioavailability and pharmacokinetics of penciclovir, a novel antiherpes agent, following oral administration of the prodrug, famciclovir
40. A further study of the effect of food on the bioavailability and pharmacokinetics of penciclovir after oral administration of famciclovir
41. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir: A randomized double-blind controlled trial in normal subjects
42. Double-blind placebo-controlled trials of oral acyclovir in first-episode genital herpes simplex virus infection
43. Intravenous acyclovir treatment for primary genital herpes
44. Intravenous acyclovir for the treatment of primary genital herpes
45. A randomized, double-blind, comparative trial comparing high- and standard-dose oral acyclovir for first-episode genital herpes infections
46. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection: Results of an international, multicenter, double-blind, randomized clinical trial
47. Oral famciclovir (FCV) a new antiherpes agent: Comparative study with acyclovir in clinic initiated treatment of first episode genital herpes (FGH)
48. Famciclovir in the management of first-episode genital herpes
49. Treatment of recurrent genital herpes simplex infections with oral acyclovir: A controlled trial
50. Double-blind placebo controlled trial of oral acyclovir in recurrent genital herpes
51. Treatment of recurrent genital herpes simplex infections with oral acyclovir
52. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections
53. Guidelines for treatment of sexually transmitted diseases: MMWR 47 (RR-1); 1-118
54. A collaborative study of patient-initiated treatment of recurrent genital herpes with topical acyclovir or placebo
55. A trial of topical acyclovir in genital herpes simplex virus infections
56. Treatment of recurrent genital herpes simplex genitalis: A controlled trial
57. A comparison of oral valaciclovir 500mg twice daily for three or five days in the treatment of recurrent genital herpes
58. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: A randomised, double-blind trial
59. Patient-initiated, twice daily oral famciclovir for early recurrent genital herpes: A randomized, double-blind multicenter trial
60. Early, clinic-initiated treatment of recurrent genital herpes using famciclovir: Results of a Canadian, multicentre study
61. Reply to: Goldman BD. Famciclovir for genital herpes
62. A double-blind study of oral aciclovir for suppression of recurrences of genital herpes simplex virus infection
63. Dosage and safety of long-term suppressive aciclovir therapy for recurrent genital herpes
64. Long-term aciclovir suppression of frequently recurring genital herpes simplex vires infection
65. Suppression of frequently recurring genital herpes: A placebo-controlled double-blind trial of oral acyclovir
66. Prolonged continuous versus intermittent oral aciclovir treatment in normal adults with frequently recurring genital herpes simplex virus infection
67. Long-term suppression of recurrent genital herpes with acyclovir: A 5-year benchmark
68. Combination therapy in primary HIV infection
69. Prolonged continuous acyclovir treatment of normal adults with frequently recurring genital herpes simplex virus infection
70. Acyclovir suppression of frequently recurring genital herpes: Efficacy and diminishing need during successive years of treatment
71. The effect of suppressive acyclovir on the psychological morbidity associated with recurrent genital herpes
72. Valaciclovir for the suppression of recurrent genital herpes simplex vires infection: A large-scale dose range-finding study
73. Oral famciclovir for the suppression of recurrent genital herpes simplex virus infection in women: A multicenter, double-blind, placebo-controlled trial
74. Oral famciclovir for the suppression of recurrent genital herpes: A randomized controlled trial
75. Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts
76. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir
77. Detection of viral DNA to evaluate outcome of antiviral treatment of patients with recurrent genital herpes
78. Famciclovir for suppression of asymptomatic and symptomatic recurrent genital herpes shedding: A randomised, double-blind, double dummy, parallel group, placebo-controlled trial
79. BID Famciclovir suppression of asymptomatic genital herpes simplex virus shedding in men
80. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons
81. Suppression of subclinical shedding of herpes simplex virus type 2 in the genital tract with valaciclovir
82. Effect of oral acyclovir treatment on symptomatic and asymptomatic virus shedding in recurrent genital herpes
83. The natural history of herpes simplex virus infection of mother and newborn
84. National surveillance for neonatal herpes simplex virus infections
85. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor
86. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection
87. The frequency of unrecognised type 2 herpes simplex virus infection among women: Implications for the control of genital herpes
88. A comparison between detailed and simple histories in the diagnosis of genital herpes complicating pregnancy
89. Genital herpes during pregnancy: Risk factors associated with recurrences and asymptomatic shedding
90. The acquisition of herpes simplex virus during pregnancy
91. Low risk of herpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent genital herpes simplex virus infections
92. The management of pregnancies complicated by genital infections with herpes simplex virus
93. Genital herpes during pregnancy: No lesions, no cesarean
94. Oral acyclovir and recurrent genital herpes during late pregnancy
95. Acyclovir suppression to prevent cesarean delivery after first-episode genital herpes
96. A randomised placebo controlled trial of suppressive acyclovir in late pregnancy in women with recurrent genital herpes infection
97. Acyclovir in late pregnancy to prevent neonatal herpes simplex
98. Acyclovir in pregnancy registry: Six years experience
99. Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes, and mouth: Results of a Phase I/II trial
100. Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy
101. Herpes simplex virus variants resistant to high concentrations of acyclovir exist in clinical isolates
102. Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir
103. Isolation and characterisation of resistant herpes simplex virus after acyclovir therapy
104. Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir
105. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome
106. Herpes simplex virus resistant to acyclovir: A study in a tertiary care centre
107. Survey of resistance of herpes simplex virus to acyclovir in northwest England
108. Occurrence and characterization of acyclovir-resistant herpes simplex virus isolates: Report on a two-year sensitivity screening survey
109. European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients
110. Acyclovir-resistant herpes simplex virus infections in a bone marrow transplant population
111. Brief report: Recurrent acyclovir-resistant genital herpes in an immunocompetent patient
112. Herpes simplex virus resistance to acyclovir: Clinical relevance
113. Disseminated acyclovir-resistant herpes simplex virus type 2 treated successfully with foscarnet
114. Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance
115. Persistent herpes simplex virus infections and mechanisms of virus drug resistance
116. In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus
117. Analysis of the thymidine kinase gene from clinically isolated acyclovir-resistant herpes simplex viruses
118. Spontaneous reactivation of thymidine kinase-deficient, acyclovir-resistant type 2 herpes simplex virus: Masked heterogeneity or reversion?
119. Acyclovir-resistant herpes simplex virus infection due to altered DNA polymerase
120. Progressive esophagitis from acyclovir-resistant herpes simplex: Clinical roles for DNA polymerase mutants and viral heterogeneity
121. Predicting and preventing the emergence of antiviral drug resistance in HSV-2
122. Trisodium phosphonoformate, a new antiviral compound
123. Foscarnet: A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections
124. Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections
125. Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immune deficiency syndrome
126. Review of the toxicities of foscarnet
127. Topical treatment of recurrent genital herpes infections with foscarnet
128. Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): Double blind, placebo controlled, multicentre study
129. Chronic vulvar ulceration in an immunocompetent woman due to acyclovir-resistant, thymidine kinase-deficient herpes simplex virus
130. Acyclovir (ACV) resistance in herpes simplex virus (HSV) isolates from a patient with esophagitis: A thymadine kinase (TK) positive, foscarnet (PFA) resistant strain with response to intravenous PFA
131. Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome
132. Chronic herpetic infection in an immunocompromised patient: Report of a case
133. Acyclovir-resistant herpes in AIDS treated with foscarnet
134. Treatment of acyclovir-resistant herpes simplex virus infections in patients with AIDS
135. Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: Preliminary data
136. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome
137. Altered sensitivity to antiviral drugs of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome
138. Foscarnet-resistant herpes simplex virus infection in patients with AIDS
139. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC)
140. Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility results for isolates of herpes simplex virus from human immunodeficiency virus-infected patients
141. Intracellular metabolism of the antiherpes agent 1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine
142. Metabolism of (S)-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine (HPMPC) in human embryonic lung cells
143. Minireview: Nucleotide prodrugs
144. Comparative activity of various compounds against clinical strains of herpes simplex virus
145. Efficacy of (S)-2-(3-hydroxy-2-phosphonyl-methoxy propyl)cytosine in various models of herpes simplex virus infection in mice
146. Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS
147. A new topical treatment for resistant herpes simplex infections
148. Biochemical basis for increased susceptibility to cidofovir of herpes simplex viruses with altered or deficient thymidine kinase activity
149. Mode of action studies on the anti-cytomegalovirus nucleoside analog [1-(2-hydroxy-1-hydroxymethyl)ethyoxy-methyl)cytosine]
150. Inhibition of herpes simplex virus DNA polymerase by diphosphates of acyclic phosphonylmethyoxalkyl nucleotide analogues
151. Selective inhibition of human cytomegalovirus DNA synthesis by (S)-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine [(S)-HPMPC] and 9-(1,3-dihydorxy-2-propoxymethyl)guanine (DHPG))
152. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: A review of their pharmacology and clinical potential in the treatment of viral infections
153. Evaluation of HPMPC therapy for primary and recurrent genital herpes in mice and guinea pigs
154. Prevention and treatment of experimental genital herpes simplex virus type 2 (HSV-2) infections with topical HPMPC
155. Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates
156. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients
157. Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects
158. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS
159. A multicenter phase I/II dose escalation study of single-dose cidofovir gel for treatment of recurrent genital herpes
160. Use of collagen shields in the treatment of herpetic keratitis
161. Topical trifluridine for mucocutaneous acyclovir-resistant herpes simplex II in AIDS patient
162. Topical trifluridine treatment of acyclovir-resistant herpes simplex disease
163. Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infections
164. Effect of cloned human interferons on protein synthesis and morphogenesis of herpes simplex virus
165. Sensitivity of herpes simplex virus 1 and 2 to three preparations of human interferon
166. Recombinant α-2 interferon in the treatment of recurrent herpes genitalis
167. Topical alpha-interferon in recurrent genital herpes simplex infection: A double-blind, placebo-controlled clinical trial
168. Topical alpha-interferon ointment with dimethyl sulfoxide in the treatment of recurrent genital herpes simplex
169. Increased effects of topically applied interferon in herpes simplex virus-induced lesions by caffeine
170. Therapy of genital herpes with topically applied interferon
171. Treatment of recurrent genital herpes with topical alpha interferon gel combined with nonoxynol 9
172. Randomized, double-blind, placebo-controlled, patient-initiated study of topical high- and low-dose interferon-α with nonoxynol-9 in the treatment of recurrent genital herpes
173. Recombinant alpha-2 interferon gel treatment of recurrent herpes genitalis
174. Placebo-controlled trial of topical interferon in labial and genital herpes
175. (+)-(1α,2b,3a)-9-[2,3-Bis (hydroxymethyl) cyclobutyl] guanine [(±)BHCG]: A potent and selective inhibitor of herpesviruses
176. Efficiency of phosphorylation of the Cyclobut-G (A-69992) enantiomers by HSV-1 thymidine kinase dose not correlate with their anti-herpesvirus activity
177. Analysis of phosphorylation pathways of antiherpesvirus nucleosides by varicellazoster virus-specific enzymes
178. Inhibition of herpes simplex virus type 1 DNA polymerase by [1R(1α,2β,3α)-9-[2,3bis(hydroxymethyl)cyclobutyl]guanine
179. Synthesis and antiviral activity of enantiomeric forms of cyclobutyl nucleoside analogues
180. Inhibitory effects of triphosphate derivatives of oxetanocin G and related compounds on eukaryotic and viral DNA polymerases and human immunodeficiency virus reverse transcriptase
181. Selective activity and cellular pharmacology of [1R-1α,2β,3α)-9-[2,3-bis-(hydroxymethyl)cyclobutyl]guanine in herpesvirus-infected cells
182. Evaluation of SQ 34,514: Pharmacokinetics and efficacy in experimental herpesvirus infections in mice
183. Lobucavir is phosphorylated in human cytomegalovirus-infected and -uninfected cells and inhibits the viral DNA polymerase
184. Efficacy of BMS-180194 against experimental cytomegalovirus infections in immunocompromised mice
185. Lobucavir (BMS-180194): A new herpesvirus topical agent effective against cutaneous infection in guinea pigs
186. Pharmacokinetics and bioavailability of cygalovir (BMS- 180194) in asymptomatic HIV- and CMV-seropositive volunteers
187. Sequential ascending multiple-dose safety and pharmacokinetic study of oral lobucavir (BMS-180194) in asymptomatic volunteers seropositive for HIV and CMV
188. Pharmacokinetics and safety of oral lobucavir in cytomegalovirus-infected HIV patients
189. Treatment of acyclovir-unresponsive cutaneous herpes simplex virus infection with topically applied SP-303
190. Safety and efficacy of Virend for topical treatment of genital and anal herpes simplex lesions in patients with AIDS
191. Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus
192. Susceptibility of recent clinical isolates of herpes simplex virus to 5-ethyl-2′-deoxyuridine: Preferential inhibition of herpes simplex virus type 2
193. Antiviral activity of 5-ethyl-2′-deoxyuridine against herpes simplex viruses in cell culture, mice, and guinea pigs
194. Comparison of topically applied 5-ethyl-2′-deoxyuridine and acyclovir in the treatment of cutaneous herpes simplex virus infection in guinea pigs
195. Randomized, double-blind, placebo-controlled, clinic-initiated, canadian multicenter trial of topical edoxudine 3.0% cream in the treatment of recurrent genital herpes
196. Immunomodulating and antiviral activities of the imidazoquinoline S-28463
197. Effect of S-28463 in reducing recurrent genital HSV-2 in guinea pigs
198. Systemic and cutaneous pharmacodynamics of topical R-848 gel in humans
199. Immunomodulation to decrease recurrences of herpes genitalis: A double-blind, dose ranging study of topical R-848
200. The concept of immune-based therapies in chronic viral infections
201. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2
202. Role of mucosal immunity in herpes simplex virus infection
203. Development of a herpes simplex virus subunit vaccine for prophylactic and therapeutic use
204. Humoral immune response to herpes simplex virus type 2 glycoproteins in patients receiving a glycoprotein subunit vaccine
205. Vaccination with recombinant herpes simplex virus glycoproteins: Protection against initial and recurrent genital herpes
206. Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs
207. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection
208. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes
209. A recombinant glycoprotein vaccine for herpes simplex virus type 2: Safety and immunogenicity
210. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: Two randomized controlled trials
211. Cervical antibody responses to a herpes simplex virus type 2 glycoprotein subunit vaccine
212. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: Results of a placebo-controlled vaccine trial
213. Multicentre clinical trial with herpes simplex virus vaccine in recurrent herpes infection
214. Gender-specific efficacy of a prophylactic SBAS4-adjuvanted gD2 subunit vaccine against genital herpes disease (GHD): Results of two clinical efficacy trials
215. Heterologous protection against influenza by injection of DNA encoding a viral protein
216. Protection of ferrets against influenza challenge with a DNA vaccine to the hemagglutinin
217. Preclinical efficacy of a prototype DNA vaccine: Enhanced protection against antigenic drift in influenza virus
218. Protection against a lethal influenza virus challenge by immunization with a hemaglutinin-expressing plasmid DNA
219. DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations
220. Vaccination with a plasmid vector carrying the rabies glycoprotein gene induces protective immunity against rabies virus
221. Bovine herpesvirus 1: Immune responses in mice and cattle injected with plasmid DNA
222. Genetic vaccination against leishmaniasis
223. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein
224. - T lymphocytes
225. DNA immunization against experimental genital herpes simplex virus infection
226. Immunogenicity of a disabled infectious single cycle HSV-2 vaccine in phase l clinical trials in HSV-2 seropositive and seronegative volunteers